TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
General issues related to the Medicare Part D Program
Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Copyright/Patent/Trademark CPT
S23 "America Invents Act" (formerly "Patent Reform Act of 2011"), HR1249, The American Invents Act.
Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Medical/Disease Research/Clinical Labs MED
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs
Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Health Issues HCR
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 and intellectual property issues in the WHO proposal; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".
Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| SANOFI SA (FORMERLY SANOFI-AVENTIS SA) | France | France | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.